Standout Papers
Citation Impact
Citing Papers
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
2014
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
2014
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
2010
Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy
2010 StandoutScience
Paradoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer
2011
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype
2008
Autonomic Nerve Development Contributes to Prostate Cancer Progression
2013 StandoutScience
PD-L1 Expression in Triple-Negative Breast Cancer
2014
Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer
2011
Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission
2009
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
2009
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
2013
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Triple negative breast cancer: unmet medical needs
2010
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer
2015
Metformin use and prostate cancer in Caucasian men: results from a population-based case–control study
2009
Breast cancer
2019 Standout
Is gene array testing to be considered routine now?
2011
Hallmarks of Cancer: The Next Generation
2011 Standout
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
2013
Triple-Negative Breast Cancer: An Unmet Medical Need
2011
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics
2016
WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
2013
Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
2012
Clinical implications of molecular heterogeneity in triple negative breast cancer
2015
Triple-Negative Breast Cancer
2010 Standout
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
2014 Standout
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging
2018
EGFR Antagonists in Cancer Treatment
2008 Standout
Neoadjuvant Therapy in the Treatment of Breast Cancer
2014
Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer
2010
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
2008
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade
2009
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX
2011
A view on drug resistance in cancer
2019 StandoutNature
Breast cancer
2016 Standout
Local Treatment of the Axilla in Early Breast Cancer: Concepts from the National Surgical Adjuvant Breast and Bowel Project B-04 to the Planned Intergroup Sentinel Mamma Trial
2014
Influence of Metabolism on Epigenetics and Disease
2013 StandoutNobel
Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients
2016
St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment
2019
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Breast cancer precursors revisited: molecular features and progression pathways
2010
Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the prospective German TMK cohort study
2017
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
2010 Standout
Intraoperative Ultrasound-Guided Excision of Axillary Clip in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Therapy (ILINA Trial)
2017
Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer
2010
Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment
2015
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Why the stroma matters in breast cancer
2012
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
2017 StandoutNobel
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
The molecular pathology of breast cancer progression
2010
The LKB1–AMPK pathway: metabolism and growth control in tumour suppression
2009
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
2017
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
2018
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Emerging Biological Principles of Metastasis
2017 Standout
The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality
2012
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
2016
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
2015
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival
2010
EMT: 2016
2016 Standout
Epithelial-Mesenchymal Transition (EMT) and Activated Extracellular Signal-regulated Kinase (p-Erk) in Surgically Resected Pancreatic Cancer
2007
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
2010
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
GOBO: Gene Expression-Based Outcome for Breast Cancer Online
2011
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
What We Talk About When We Talk About Fat
2014 Standout
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
2012
Epidemiological aspects of neoplasms in diabetes
2010
Clonal evolution in cancer
2012 StandoutNature
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
2013
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy
2015
Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art
2017
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
Chemotherapy in Early Breast Cancer: When, How and Which One?
2014
An “elite hacker”
2012
Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy
2015
Comprehensive Integration of Single-Cell Data
2019 Standout
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression
2014
Polymorphisms, Mutations, and Amplification of the EGFR Gene in Non-Small Cell Lung Cancers
2007
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
2010
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer Patients
2014
Pattern of metastatic spread in triple-negative breast cancer
2008
Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments
2018
Deconstructing the molecular portraits of breast cancer
2010
Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology
2015
Adenosine Monophosphate-Activated Protein Kinase: A Central Regulator of Metabolism with Roles in Diabetes, Cancer, and Viral Infection
2011
Axillary Nodal Management Following Neoadjuvant Chemotherapy
2016
Paracrine and Endocrine Effects of Adipose Tissue on Cancer Development and Progression
2011
Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas
2006
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
2009
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes
2009
One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA
2021 StandoutNobel
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
2015
Immune Landscape of Breast Cancers
2018
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Diabetes and Cancer
2010 Standout
Breast Cancer Treatment
2019 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Immune targeting in breast cancer.
2015
Surgical treatment of primary breast cancer in the neoadjuvant setting
2014
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2014
Current Status of Src Inhibitors in Solid Tumor Malignancies
2011
Prognostic and predictive value of PDL1 expression in breast cancer
2014
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance)
2015
Layer-by-Layer Nanoparticles for Systemic Codelivery of an Anticancer Drug and siRNA for Potential Triple-Negative Breast Cancer Treatment
2013
Metabolic reprogramming and cancer progression
2020 StandoutScience
Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection
2016
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
2018 StandoutNobel
Autophagy and Metabolism
2010 StandoutScience
Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells
2013 StandoutScience
Global cancer statistics, 2012
2015 Standout
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer
2011
Works of Cornelia Liedtke being referenced
Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy
2010
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
2008 Standout
Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array
2009
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
2009
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
2013 Standout
Personalized treatment of early-stage breast cancer: Present concepts and future directions
2010
Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines
2009
Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
2011
A clinically relevant gene signature in triple negative and basal-like breast cancer
2011
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2016
2016
Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma
2004
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation
2011
AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015
2015
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
2016
The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?
2005
Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial.
2015
Evaluation of biological pathways involved in chemotherapy response in breast cancer
2008
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer
2019
Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study
2015
Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer
2009
Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
2009